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Abstract
To pursue a systematic approach to discovery of mechanisms of action of traditional Chinese medicine (TCM), we used
microarrays, bioinformatics and the ‘‘Connectivity Map’’ (CMAP) to examine TCM-induced changes in gene expression. We
demonstrated that this approach can be used to elucidate new molecular targets using a model TCM herbal formula Si-Wu-
Tang (SWT) which is widely used for women’s health. The human breast cancer MCF-7 cells treated with 0.1 mM estradiol or
2.56 mg/ml of SWT showed dramatic gene expression changes, while no significant change was detected for ferulic acid, a
known bioactive compound of SWT. Pathway analysis using differentially expressed genes related to the treatment effect
identified that expression of genes in the nuclear factor erythroid 2-related factor 2 (Nrf2) cytoprotective pathway was most
significantly affected by SWT, but not by estradiol or ferulic acid. The Nrf2-regulated genes HMOX1, GCLC, GCLM, SLC7A11 and
NQO1 were upreguated by SWT in a dose-dependent manner, which was validated by real-time RT-PCR. Consistently,
treatment with SWT and its four herbal ingredients resulted in an increased antioxidant response element (ARE)-luciferase
reporter activity in MCF-7 and HEK293 cells. Furthermore, the gene expression profile of differentially expressed genes related
to SWTtreatment was used to comparewiththoseof 1,309 compoundsin the CMAP database.TheCMAP profiles of estradiol-
treated MCF-7 cells showed an excellent match with SWT treatment, consistent with SWT’s widely claimed use for women’s
diseases and indicating a phytoestrogenic effect. The CMAP profiles of chemopreventive agents withaferin A and resveratrol
also showed high similarity to the profiles of SWT. This study identified SWT as an Nrf2 activator and phytoestrogen,
suggesting its use as a nontoxic chemopreventive agent, and demonstrated the feasibility of combining microarray gene
expression profiling with CMAP mining to discover mechanisms of actions and to identify new health benefits of TCMs.
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Introduction
Traditional Chinese medicines (TCMs) have been used in China
and other Asian countries for over 5,000 years for the prevention
and treatment of a variety of diseases. In contrast to target-oriented
Western medicine, TCM uses a holistic and synergistic approach to
restore the balance of Yin-Yang of body energy so the body’s normal
function, or homeostasis, can be restored [1]. Traditional Chinese
herbal medicines often consist of a combination of individual herbs
to form specific formulae aimed to increase therapeutic efficacy and
reduce adverse effects [2]. Theoretically, multiple active phyto-
chemical components in the TCM formulae may simultaneously
target multiple molecules/pathways and thus potentially achieve
superior effect as compared to single compounds alone [3].
However, while about 100,000 herbal formulae have been recorded
and there are many empiric examples of successful clinical use of
TCM, relationship of the essential phytochemical components in
each of the formulae to molecular targets/pathway has not been
identified for most TCM due to lack of suitable methodology to
tackle the complex mechanisms. Lack of molecular evidence for
targets diminishes the scientific validity of the claimed usefulness of
TCM, despite the availability of empiric clinical experience. Thus,
new methods for molecular target/pathway identification are sorely
needed to advance the modernization of TCM.
The microarray technology and associated bioinformatic data
mining tools provide an opportunity to simultaneously analyze a
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18278large number of genes/targets associated with complex therapeu-
tic effects of TCM [4]. The working principle for this genomic
approach is that the phenotype of a cell, including the function
and response to the environment, is ultimately determined by its
gene expression profiles. Analyzing the changes of gene expression
profiles after treatment by TCM in vitro or in vivo may help reveal
their mechanisms of action [4,5]. In addition, because the use of
medicinal herbs may mimic or oppose the effects of concurrently
used drugs, gene expression profiling using microarrays can also be
used for revealing the mechanism of herb-drug interactions [6].
A few studies have used microarray-based transcriptional
profiling to evaluate TCMs or their components [5,7,8,9,10].
The identified genes modulated by the TCM provided insights
into molecular understanding of activity [4,11]. However, the real
challenge is to reliably detect differentially expressed genes and
dissect the functional relevance of identified genes to pharmaco-
logical mechanisms from these microarray studies [12]. The
improper study design and unsuitable data analysis may lead to
unreliable and less accurate results derived from the microarray
studies [13,14,15,16]. To compare and integrate data derived
from multiple different array experiments even for a single TCM
component represents another technical challenge [12]. Special
quality control criteria for array processing and analysis need to be
used to overcome previous problems associated with microarray
technologies.
Recently, the Connectivity Map (CMAP) database containing
microarray expression data from cultured cell lines (e.g., human
breast cancer cell line MCF-7) treated with bioactive small
molecules with known mechanism of action and disease application
has been described [17]. The current version of CMAP contains
more than 7,000 expression profiles representing treatments from
1,309 compounds (http://www.broadinstitute.org/cMAP/) and in
several studies, the CMAP database has been used for discovery of
functional connections between drugs, genes, and diseases through
the common gene-expression changes on the same cell lines
[17,18,19,20,21]. Using CMAP, drugs affecting common molecular
pathways can be identified and putative mechanism of action of
unknown drugs can be explored. It may provide a useful tool for
TCM when combined with microarray analysis.
To demonstrate the potential application of this approach for
discovery of molecular mechanisms of TCM, we studied a model
TCM formula, Si-Wu-Tang (SWT, directly translated as Four
Agents Decoction) [22]. SWT has been used in China and Japan
for about 1,000 years for the relief of menstrual discomfort,
climacteric syndrome, peri- or postmenopausal syndrome and
other estrogen-related diseases [22,23,24,25,26]. It has been
reported to have sedative, anti-coagulant and antibacterial
activities as well as effects on vasodilatation and hematopoiesis
[27]. SWT has also been shown to possess an inhibitory effect on
radiation-induced bone marrow damage [27,28]. However, the
mechanism of the pharmacological action of SWT has not yet
been clarified. The SWT formula is composed of four herbs,
Radix Rehmanniae praeparata, Radix Angelicae Sinensis, Rhizoma
Ligustici Chuanxiong and Radix Paeoniae Alba [22]. At least nine
bioactive phytochemicals have been reported for SWT: paeoni-
florin, paeonol, gallic acid, ferulic acid, Z-ligustilide, ligustrazine,
butylphthalide, senkyunolide A and catalpol [25]. Of these
compounds, ferulic acid (FA) and paeoniflorin have been
recommended as the chemical markers for quality assessment of
SWT [29,30,31,32]. In view of wide empiric use of SWT and
known chemical components already reported, in the present
study, we profiled the gene expression of MCF-7 cells treated with
SWT, its component FA as well as estradiol using Affymetrix
microarray Human U133Plus2.0 (Figure 1). We demonstrated the
feasibility of applying the combined microarray and CMAP
approach in identifying molecular mechanisms of SWT.
Results
Hierarchical clustering analysis for quality assessment of
array data and identification of treatment effects
Hierarchical clustering analysis was used to assess the overall
quality of the microarray data (Figure 2a). A high correlation
coefficient (colored in red in the heatmap of correlation
coefficients) means that the gene expression profiles from two
microarrays are very similar. The three replicates in each
treatment group showed high pair-wise correlation in terms of
log2 gene expression. In addition, samples treated with estradiol
and high concentration of SWT showed dramatically different
expression profiles compared to that of the control group. The
visual observation of the clustering results indicates satisfactory
reproducibility of microarray experiments for the biological
replicates in each treatment group and significant treatment
effects of estradiol and SWT, warranting further analyses and
interpretation of their treatment effects.
Three replicates of MCF-7 control and MCF-7 treated with
ferulic acid at low, medium and high concentrations were used for
hierarchical clustering analysis in Figure 2b. For every dose-
treatment group, the three replicates in the same group did not
cluster together, indicating that there was no clear treatment effect
even at the high concentration of ferulic acid. It seems that the
treatment effects of ferulic acid on MCF-7 are minimal at the
doses tested in this study.
In inspecting the treatment effects of SWT at low, medium and
high concentrations along with the three replicates of estradiol
treatment, hierarchical clustering analysis (Figure 2c) clearly
demonstrated the high reproducibility of the replicates in each
treatment group and strong treatment effects for estradiol and
SWT at high concentration. The figure also shows clustering of the
three replicates in the medium or low concentration of SWT
treatment, but the degree of the treatment effect was much smaller
than that for high-concentration SWT treatment. The expression
profiles for the three replicates in the estradiol treatment group
also clustered tightly together and were dramatically different from
those of the control group samples. The expression profiles of the
estradiol group were also dramatically different from those of the
high-concentration SWT treatment group.
Identification of differentially expressed genes
Because there are 54,675 probe sets on the Affymetrix Human
U133Plus 2.0 microarray, 2,734 probe sets would be expected by
chance to show a p,0.05. By comparing the number of probe sets
with a p,0.05 for each treatment group (Table 1) with that
expected by chance (2,734), we can roughly assess the degree of
the treatment effect. By applying the same cutoffs of t-test p value
,0.05 and fold change .1.5, the differentially expressed genes
were selected separately from comparing each treatment group
with the control group. The number of differentially expressed
genes varied dramatically depending on the treatment group. The
high-concentration SWT and estradiol treatments resulted in the
highest numbers of genes differentially expressed, whereas the
treatment effect of ferulic acid appeared to be minor for all
concentrations, and there was no clear dose-response relationship.
On the other hand, the numbers of genes differentially expressed
as a result of SWT treatment showed a clear dose-response trend,
with an increase from low dose (7 genes, corresponding to 10
probe sets) to medium dose (71 genes, corresponding to 90 probe
sets) and a big jump from medium dose to high dose (1,911 genes,
Mechanistic Study of Si-Wu-Tang
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(0.1 mM) changed the expression of 830 unique genes (corre-
sponding to 1,292 probe sets). However, only 337 genes were
commonly regulated by both estradiol treatment and the high-
concentration SWT treatment, indicating similarities and differ-
ences in the mechanisms of action between the two agents.
Consistently, by controlling the false discovery rate (FDR) at the
level of 0.05, only the high-concentration SWT and estradiol
treatments resulted in genes differentially expressed (Table 1).
Canonical pathway analysis by IPA software: the Nrf2-
mediated oxidative stress response pathway is most
significantly impacted by high-concentration SWT
treatment
The pathway names, Fisher’s exact test p values, and the ratios
of impacted genes for the top 10 IPA pathways most significantly
enriched with genes differentially expressed from SWT and
estradiol treatments are listed in Table 2. For the low-
concentration SWT treatment, none of the IPA pathways was
significantly enriched, mainly because of the very small number of
differentially expressed genes (10 probe sets, corresponding to 7
genes). For medium-concentration SWT treatment, several IPA
pathways related to the metabolism of xenobiotics by CYP450,
C21-steroid hormone metabolism, cell cycle, and molecular
mechanisms of cancer were highly enriched with differentially
expressed genes. Genes differentially expressed from high-
concentration SWT treatment group were most significantly
enriched in several cancer signaling pathways. In particular, the
Nrf2-mediated oxidative stress response pathway, which has
recently been found to play an important role in cancer
prevention, was the most significantly impacted pathway
(p=4.55610
29). About 23% (42/183) of the genes in the Nrf2
pathway were either up- or down-regulated by high-concentration
SWT treatment (Figure 3).
We also used the expression profile of estradiol treatment as the
query to search the IPA pathway database. The top 10 hits
(Table 2) include pathways related to cell cycle, molecular
mechanisms of cancer, and p53 signaling. These pathways are
well-known to be associated with the biological functions of
estradiol, validating the quality of microarray gene expression data
in this study and the utility of the IPA pathway analysis approach.
Notably, although the Nrf2-mediated oxidative stress response
pathway was significantly impacted by high-concentration SWT
treatment, it was not affected by estradiol treatment at the
condition tested in this study.
Pathway analysis in KEGG database
None of the KEGG pathways was significantly enriched with
the differentially expressed genes from low-concentration SWT
treatment group and only 8 KEGG pathways were significantly
enriched from medium-concentration SWT treatment. Instead,
there were 25 and 19 KEGG pathways significantly enriched with
differentially expressed genes from high-concentration SWT
treatment and estradiol treatment, respectively. The top 10
significantly impacted KEGG pathways were listed in Table 3.
Comparing the KEGG pathways listed in Table 3 with the IPA
pathways listed in Table 2, we can see that pathways related to
signaling of cancer, cell cycle and metabolism were significantly
Figure 1. Experimental design of microarray gene expression profiling. The 24 samples were obtained from MCF-7 cells which were divided
into eight treatment groups. 0.001% DMSO was used as the vehicle control (C). The cells were treated with 0.1 mM estradiol, FA at three
concentrations (0.1, 1.0, and 10 mM) and SWT at three concentrations (0.0256, 0.256, and 2.56 mg/ml). For each treatment group, 3 biological
replicates were included.
doi:10.1371/journal.pone.0018278.g001
Mechanistic Study of Si-Wu-Tang
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medium- and high-concentrations, highlighting the commonalities
between the pharmacological effects of estradiol and SWT.
Identification of dose-responsive genes and pathways
Since genes or pathways that show dose-dependent changes are
most likely reflecting valid pharmacological action from a drug, we
therefore created two lists of differentially expressed genes (probe
sets, p,0.05) from SWT treatments at medium and high
concentrations in comparison to the controls and identified
common genes by overlapping the two lists. From this list of
common genes, we can determine dose-responsive genes for which
the expression level increased or decreased and mapped these to
unique gene symbols in the IPA software. In total, 1,240 unique
Figure 2. The hierarchical clustering analysis and heatmap of the correlation coefficients between gene expression profiles. (A) All
24 samples from the 8 treatment groups; (B) controls and ferulic acid treatments; and (C) controls and treatments by estradiol and SWT. There was
good reproducibility between the three biological replicates in each treatment group. No clear treatment effect was observed for ferulic acid
treatments. Low- and medium-concentration SWT treatments showed mild effects, while the strongest treatment effects were seen from estradiol
and high-concentration SWT treatments.
doi:10.1371/journal.pone.0018278.g002








No. of probe sets
(p,0.05)*
No. of probe sets
(FDR,0.05)
Control - C1, C2, C3 - - - -
Estradiol 0.1 mM EM1, EM2, EM3 1,292 830 11,595 3,598
Ferulic acid 0.1 mM FL1, FL2, FL3 9 8 2,965 0
1 mM FM1, FM2, FM3 6 4 3,332 0
10 mM FH1, FH2, FH3 3 3 2,270 0
SWT 0.0256 mg/mL SL1, SL2, SL3 10 7 3,578 0
0.256 mg/mL SM1, SM2, SM3 90 71 5,409 0
2.56 mg/mL SH1, SH2, SH3 2,979 1911 13,296 6,673
*For the U133Plus2 microarrays with 54,675 probe sets, 2,734 (54,67560.05) probe sets are expected by chance to have a p value ,0.05.
FDR: false discovery rate.
doi:10.1371/journal.pone.0018278.t001
Mechanistic Study of Si-Wu-Tang
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with the pathways in the IPA software. The intensity of these genes
obviously increased or decreased when the concentration of SWT
treatments increased from 0.0256 mg/mL (SL) to 2.56 mg/mL
(SH). Table 4 lists the names, Fisher’s exact test p values, and the
ratios of affected genes for the top 10 IPA pathways most
significantly enriched with the dose-responsive genes to SWT. The
Nrf2 pathway is again on the top of list. Among all the 1,240 genes
showing dose-responsive changes, 24 upregulated and 7 down-
regulated genes could be assigned to the Nrf2 pathway. Figure 4
showed that 10 out of the15 most upregulated genes (probe sets)
are regulated by the Nrf2 pathway according to PubMed literature
search. Because of recently reported cancer prevention role of the
Nrf2 pathway, our data suggest that SWT may have an Nrf2-
inducing activity and may possess cancer chemopreventive effects.
Mapping gene expression profiles to the CMAP reference
database
Since the same cell line (MCF-7) and same treatment period
(6 h) were used to generate the above dataset as the CMAP
dataset, comparison analysis can be done between the two
datasets. Estradiol is the common drug used in both datasets.
Thus, to further evaluate the quality and usability of the gene
expression data generated in this study, we first used the gene
expression profile from estradiol treatment as a query to search the
CMAP database. If our data are in good quality and the CMAP
approach works, we should expect the gene expression profiles of
MCF-7 cells treated with estradiol in CMAP to show up on the list
of top hits. Indeed, when the top 200 (100 up-regulated and 100
down-regulated) differentially expressed genes were used as the
query, the CMAP profile of estradiol treated MCF-7 cells surfaced
Table 2. Top IPA pathways enriched with differentially expressed genes and their corresponding Fisher’s exact test p values.
Treatment IPA pathway name p-value
Total number of genes




Nrf2-mediated Oxidative Stress Response 4.55e-09 183 0.230
p53 Signaling 2.37e-07 92 0.283
Molecular Mechanisms of Cancer 6.17e-07 372 0.164
Glucocorticoid Receptor Signaling 3.68e-06 280 0.168
CD40 Signaling 2.92e-05 67 0.254
Pancreatic Adenocarcinoma Signaling 3.26e-05 116 0.207
EGF Signaling 3.26e-05 49 0.286
B Cell Receptor Signaling 7.57e-05 154 0.188
TGF-b Signaling 8.81e-05 83 0.229
HGF Signaling 1.22e-04 103 0.214
SWT at medium
concentration
Cell Cycle: G1/S Checkpoint Regulation 4.28e-05 59 0.068
Role of CHK Proteins in Cell Cycle Checkpoint Control 2.27e-04 35 0.086
Aryl Hydrocarbon Receptor Signaling 1.18e-03 154 0.026
Molecular Mechanisms of Cancer 1.21e-03 372 0.016
C21-Steroid Hormone Metabolism 2.11e-03 71 0.028
Metabolism of Xenobiotics by Cytochrome P450 3.47e-03 209 0.014
TR/RXR Activation 3.71e-03 97 0.031
p53 Signaling 4.22e-03 92 0.033
Cell Cycle Regulation by BTG Family Proteins 7.06e-03 36 0.056
ATM Signaling 1.46e-02 53 0.038
SWT at low
concentration
None of the pathways was significantly
enriched with differentially expressed genes.
Estradiol Role of BRCA1 in DNA Damage Response 5.10e-09 61 0.246
Cell Cycle: G1/S Checkpoint Regulation 2.69e-07 59 0.220
Role of CHK Proteins in Cell Cycle Checkpoint Control 6.22e-06 35 0.257
Aryl Hydrocarbon Receptor Signaling 7.09e-06 154 0.117
Hereditary Breast Cancer Signaling 1.85e-05 129 0.124
Molecular Mechanisms of Cancer 2.80e-05 372 0.083
Pyrimidine Metabolism 5.74e-05 231 0.078
Glycosphingolipid Biosynthesis - Globoseries 3.86e-04 46 0.130
p53 Signaling 3.87e-04 92 0.130
Pancreatic Adenocarcinoma Signaling 1.21e-03 116 0.103
*The ratio is calculated by dividing the number of differentially expressed genes found in the pathway by the total number of genes involved in the pathway.
doi:10.1371/journal.pone.0018278.t002
Mechanistic Study of Si-Wu-Tang
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e18278Figure 3. The Nrf2-mediated oxidative stress response pathway in IPA database. The red color and green color indicate the up- and down-
regulated genes after treatment with high-concentration of SWT in this pathway, respectively.
doi:10.1371/journal.pone.0018278.g003
Mechanistic Study of Si-Wu-Tang
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profiles resulting from treatments of three compounds, including
butyl hydroxybenzoate, alpha-estradiol and genistein, were also on
the top of the hit list. These compounds have been known to share
the same molecular mechanisms of action with estradiol, mainly
by regulating the hormonal signal transduction systems. Interest-
ingly, the profile from treatment with fulvestrant, also known as
ICI 182,780, turned out to be most contradictory to that from
estradiol in our study, with a mean score of -0.806. This finding is
consistent with the mechanistic role of fulvestrant, a pure estrogen
receptor antagonist with no agonist effect for treating hormone
receptor-positive metastatic breast cancer in postmenopausal
women. These results from estradiol treatment indicated the
value of the CMAP reference database and enhanced our
confidence in the reliability of the microarray data from our study.
We also used the gene expression profiles of 100 up-regulated
and 100 down-regulated genes from high-concentration SWT
treatment and all the 53 differentially expressed genes from
medium-concentration SWT treatment to query the CMAP
database. For the low-concentration SWT treatment, CMAP
search could not be performed because there were no down-
regulated genes. The CMAP gene expression profile of MCF-7
treated with estradiol was the only one showing significant match
(permutation p,0.00001) for both high- and medium-concentra-
tion SWT, indicating that SWT has an effect on MCF-7 cells
similar to that of estradiol. This finding appeared to be consistent
with SWT’s widely claimed use as a TCM for women’s diseases.
The CMAP profiles of several other compounds (including
phenoxybenzamine, withaferin A, 15-delta prostaglandin J2 and
resveratrol) also showed high similarity to that of high-concentra-
tion SWT treatment. The pharmacological effects of these
compounds are not similar to that of estradiol, suggesting that
SWT has additional effects not seen with estradiol.
Validation of the microarray gene expression data by
real-time RT-PCR
The differential expression of five genes in the Nrf2 pathway in
response to SWT was validated by quantitative real-time RT-PCR
on samples obtained from MCF-7 cells treated in a separate
experiment. The selected genes are HMOX1 (Heme oxygenase 1,
HO-1), GCLC (glutamate-cysteine ligase, catalytic subunit), GCLM
(glutamate-cysteine ligase, modifier subunit), NQO1 (NAD(P)H:-
quinine oxidoreductase 1) and SLC7A11 [solute carrier family 7,
(cationic amino acid transporter, y+ system) member 11]. The fold
Table 3. Top KEGG pathways enriched with differentially expressed genes and their corresponding Fisher’s exact test p values.
Treatment KEGG pathway name (Entry ID) p-value
SWT at high concentration MAPK signaling pathway (hsa04010) 4.81e-05
TGF-beta signaling pathway (hsa04350) 7.76e-05
Colorectal cancer (hsa05210) 9.76e-05
Acute myeloid leukemia (hsa05221) 1.26e-04
p53 signaling pathway (hsa04115) 8.88e-04
Apoptosis (hsa04210) 9.54e-04
Axon guidance (hsa04360) 1.28e-03
Bladder cancer (hsa05219) 1.52e-03
Glutamate metabolism (hsa00251) 2.60e-03
Chronic myeloid leukemia (hsa05220) 2.73e-03
SWT at medium concentration p53 signaling pathway (hsa04115) 4.36e-04
Bladder cancer (hsa05219) 1.42e-03
Prion disease (hsa05060) 2.49e-03
Cell cycle (hsa04110) 3.12e-03
Metabolism of xenobiotics by cytochrome P450 (hsa00980) 6.13e-03
Small cell lung cancer (hsa05222) 1.12e-02
Tetrachloroethene degradation (hsa00625) 3.76e-02
Acute myeloid leukemia (hsa05221) 3.79e-02
SWT at low concentration None of the pathways was significantly enriched with differentially expressed genes.
Estradiol Cell cycle (hsa04110) 1.00e-08
Purine metabolism (hsa00230) 5.69e-04
Porphyrin and chlorophyll metabolism (hsa00860) 3.18e-03
Glycosphingolipid biosynthesis - globoseries (hsa00603) 3.70e-03
p53 signaling pathway (hsa04115) 5.18e-03
Pentose and glucuronate interconversions (hsa00040) 6.21e-03
One carbon pool by folate (hsa00670) 6.24e-03
Pyrimidine metabolism (hsa00240) 9.69e-03
Thyroid cancer (hsa05216) 1.19e-02
Bladder cancer (hsa05219) 1.49e-02
doi:10.1371/journal.pone.0018278.t003
Mechanistic Study of Si-Wu-Tang
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were concordant with those obtained by microarrays (Table 6).
The magnitude of the fold change from the RT-PCR assay was
greater than that from the microarrays.
Effects of SWT on activation of Nrf2/ARE by dual
luciferase reporter gene assay
In order to measure the activation of the Nrf2 pathway, a 39-bp
ARE-containing sequence from the promoter region of the human
NQO1 gene was inserted into the cloning site of the luciferase
plasmid pGL4.22 and then transiently transfected into MCF-7
cells. This assay was firstly established using HEK293 cells with
sulforaphane as a positive control (Figure 5A). The transfected
cells were then treated with SWT (SL, SM and SH) and the four
individual herbal ingredients. A dual luciferase reporter gene assay
was used in which a renilla luciferase gene was used as an internal
control for normalization of the transfection efficiency and for
toxicity induced during drug exposure. The high concentration of
Table 4. Top IPA pathways enriched with genes showing dose-responsive changes after SWT treatment and corresponding
Fisher’s exact test p values.
Ingenuity canonical pathways p value Total number of genes in IPA pathway Ratio
Nrf2-mediated Oxidative Stress Response 4.9E-05 183 0.169
Chronic Myeloid Leukemia Signaling 0.0001 105 0.190
PPAR Signaling 0.0001 98 0.194
Glutamate Metabolism 0.0002 78 0.141
Cell Cycle: G1/S Checkpoint Regulation 0.0002 59 0.237
Small Cell Lung Cancer Signaling 0.0003 89 0.180
Protein Ubiquitination Pathway 0.0003 201 0.149
Molecular Mechanisms of Cancer 0.0004 372 0.126
mTOR Signaling 0.0005 156 0.154
PI3K/AKT Signaling 0.0007 137 0.153
*The ratio is calculated by dividing the number of differentially expressed genes found in the pathway by the total number of genes involved in the pathway.
doi:10.1371/journal.pone.0018278.t004
Figure 4. Dose-responsive genes with the largest fold changes. Among 15 dose-responsive up-regulated genes (probe sets) with the largest
fold changes, ten are related to Nrf2 (highlighted in red box) according to PubMed literature search.
doi:10.1371/journal.pone.0018278.g004
Mechanistic Study of Si-Wu-Tang
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Treatment* CMap chemical name and cell line Mean score p-value
SWT at high concentration Phenoxybenzamine - MCF7 0.964 ,0.00001
Withaferin A - MCF7 0.885 ,0.00001
Securinine - MCF7 0.781 0.00002
15-delta prostaglandin J2 - MCF7 0.697 ,0.00001
Thioridazine - MCF7 0.436 ,0.00001
Resveratrol - MCF7 0.432 ,0.00001
Estradiol - MCF7 0.345 ,0.00001
Tanespimycin - MCF7 0.188 ,0.00001
0317956-0000 - MCF7 20.58 ,0.00001
Fulvestrant - MCF7 20.698 ,0.00001
SWT at medium concentration Estradiol - MCF7 0.504 ,0.00001
Genistein - MCF7 0.452 ,0.00001
Valproic acid - MCF7 20.367 0.00008
Trichostatin A - HL60 20.392 ,0.00001
LY-294002 – HL60 20.428 ,0.00001
LY-294002 – MCF7 20.445 0.00004
Sirolimus - MCF7 20.493 ,0.00001
Trichostatin A - MCF7 20.658 ,0.00001
Vorinostat - MCF7 20.608 0.00002
Fulvestrant - MCF7 20.765 ,0.00001
SWT at low concentration There were no down-regulated genes and
CMap search could not be performed.
Estradiol Butyl hydroxybenzoate - MCF7 0.826 ,0.00001
Estradiol - MCF7 0.667 ,0.00001
Genistein - MCF7 0.632 ,0.00001
Alpha-estradiol - MCF7 0.544 ,0.00001
Trichostatin A - MCF7 20.427 ,0.00001
0317956-0000 - MCF7 20.434 ,0.00001
Vorinostat - MCF7 20.457 ,0.00001
Phenoxybenzamine - MCF7 20.496 ,0.00001
Pyrvinium - MCF7 20.561 ,0.00001
Fulvestrant - MCF7 20.806 ,0.00001
*For high-concentration SWT and estradiol treatments, the query to CMAP search included 100 up-regulated and 100 down-regulated genes. For medium-
concentration SWT treatment, all the 53 differentially expressed genes (3 down-regulated and 50 up-regulated) were used as the query for CMAP search.
doi:10.1371/journal.pone.0018278.t005
Table 6. The gene expression fold changes of RT-PCR in comparison with the microarrays.
SL SM SH
Gene Microarray RT-PCR Microarray RT-PCR Microarray RT-PCR
SLC7A11 1.1460.09 0.8060.03 2.0760.17** 1.3360.16* 5.2160.43** 8.3860.13**
HMOX1 1.1360.14 1.6360.07 2.2560.11** 5.7360.55* 8.3560.12** 45.9960.53**
GCLC 1.0160.08 3.5860.12 1.4260.02** 4.0160.14* 3.1260.06** 17.2760.03**
GCLM 1.1460.09* 1.0660.12 1.6560.07* 1.3160.04* 4.3860.33** 6.3260.11**
NQO1 0.9860.01 1.20 1.0860.03 1.39 1.0160.04 2.28
*P,0.05.
**P,0.01.
The standard deviation (SD) is not applicable for NQO1 gene, for which the PCR was performed for one time.
doi:10.1371/journal.pone.0018278.t006
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activity, while the individual herbs increased the luciferase activity
to a higher degree (Figure 5B). Rehmanniae was found to be
strongest activator for Nrf2/ARE transcription. Similar results
have been obtained in another cell line HEK293 cells (data not
shown). These results suggest that SWT and its ingredients may
upregulate the expression of the Nrf2 target genes by activating the
ARE on the promoters of these genes.
Discussion
The use of TCM is widespread in China and many Asian countries,
and is also rapidly growing in Western countries [3]. Despite its long
history of use, many questions remain to be answered due to lack of
mechanistic understanding. In this study, we demonstrated, for the first
time, a combined microarray gene expression and CMAP data mining
approach to discover the mechanisms of action and to identify new
therapeutic uses for TCM. We used a popular TCM formula SWT as
a model to demonstrate the potential application of this approach.
The array data for 24 samples were firstly analyzed by
hierarchical clustering analysis for a quality assessment of the
array data and for a comparison of the treatment effects. The three
biological replicates in each treatment group showed a high
reproducibility in the microarray experiments. The clustering
results and the numbers of differentially expressed genes in each
treatment group also revealed that the gene expression profile of
MCF-7 cells was strongly changed by the treatment with estradiol
and high-concentration of SWT, but not by FA and low-
concentration SWT. The pathway analysis identified the Nrf2-
mediated oxidative stress response as the pathway most signifi-
cantly changed among differentially expressed genes showing
dose-dependent response to SWT treatment. This new finding
suggests that SWT could be cancer preventive. The real-time PCR
data showed a similar but higher degree of gene upregulation of
select genes in the Nrf2 pathway. When the gene expression
profiles of MCF-7 cells resulting from SWT treatment were used
to compare with those from 1,309 compounds in the CMAP
database, the CMAP gene expression profile of estradiol-treated
MCF-7 cells turned out to be the best match, consistent with
SWT’s widely claimed use for women’s diseases and suggesting a
potential phytoestrogenic effect. The CMAP profiles of several
compounds with chemopreventive activity, i.e., withaferin A and
resveratrol, also showed high similarity to the profiles of SWT.
Figure 5. Luciferase assay results. (A) Luciferase assay established using HEK-293 cells co-transfected with a plasmid containing an ARE-luciferase
reporter gene (pGL4.22-ARE) or empty vector (pGL4.22) and a plasmid encoding renillar luciferase (pGL4.74). The transfected cells were treated with
sulforaphane for 24 hr prior to measurement of firefly and renillar luciferase activities using the dual luciferase reporter gene assay. (B) SWT (three
doses SL, SM and SH in 0.0256, 0.256 and 2.56 mg/ml) and four herbal components of SWT (2.56 mg/ml) activated the Nrf2/ARE signaling pathway in
MCF-7 cells.
doi:10.1371/journal.pone.0018278.g005
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in the Nrf2 signaling pathway was strongly impacted by SWT, but
not by estradiol or ferulic acid treatment. The Nrf2 (nuclear factor
erythroid 2 -related factor 2), a basic zip (bZIP) transcription
factor, has been known as a key molecular target for chemopre-
ventive agents, in particular, natural products and phytochemicals
with activities in chemoprevention (for reviews, see [33] and [34]).
Nrf2 plays a central role in the regulation of basal and/or
inducible expression of phase II genes by binding to the
antioxidant response elements (AREs) in their promoters [35].
Nrf2 is normally sequestered in the cytoplasm by Kelch-like ECH-
associated protein 1 (Keap1). When activated upon exposure to
inducers, it dissociates from Keap1, translocates to the nucleus,
complexes with other nuclear factors, and binds to the ARE of
genes. Chemopreventive Nrf2 inducers affect the interaction
between Keap1 and Nrf2 through several mechanisms such as
redox-sensitive modifications on cysteine residues of Keap1 or
other cellular sensors and phosphorylation of Nrf2 [36]. Consistent
with our results, the extract of Angelicae Sinensis (Dang Gui), one of
the four herbal ingredients of SWT, has been shown to induce the
expression of the detoxification enzyme NAD(P)H:quinine oxido-
reductase 1 (NQO1), which is regulated by the Nrf2 pathway [37].
One of the active compounds, Z-ligustilide, was found with strong
NQO1 inducing property by alkylating Keap1 [37]. We have also
tested the effects of Z-liguistilide treatment on MCF-7 cells on
Nrf2 gene expression and obtained the similar inducing effects
(unpublished results).
The Nrf2-inducing activity of SWT represents an intriguing and
interesting finding. SWT and its components, by affecting multiple
Nrf2 target genes, could impact multiple components of the
carcinogenic process. Many of the downstream target genes of
Nrf2 are important in maintaining the cellular antioxidative
response and amelioration of oxidative stress [38]. For example,
the glutamate-cysteine ligase and SLC7A11 are essential in
regulating the synthesis of glutathione, a very powerful endoge-
nous antioxidant [39]. The NAD(P)H quinone oxidoreductase 1
(NQO1) catalyzes the reduction and detoxification of highly
reactive quinones that can cause oxidative stress [40]. HO-1
(HMOX1) has been shown to protect from a variety of
pathologies, including sepsis, hypertension, atherosclerosis, acute
lung injury, kidney injury, and pain [41]. In addition, the effect of
SWT on cytoprotective and detoxification pathways may explain
other clinical effects of SWT. For example, its bone marrow
protective effect on irradiated mice [27,28,42] may be attributed
to the Nrf2-induding effects which may increase the radioresis-
tance of bone marrow stem cells. It is also noted that many of
Nrf2-regulated genes showed dose-dependent upregulation by
SWT, but not by estrogen or ferulic acid. This suggests that the
Nrf-2 activating effects of SWT may be separated from its
phytoestrogenic effect. Further studies are needed to clarify the
effect from different compounds compared to the whole SWT
formula.
The identified differentially expressed genes in each treatment
group were used in the comparison with the CMAP reference
database [17]. We can directly compare the expression profiles of
estradiol in our dataset and with those in the CMAP dataset due to
the same cell line (MCF-7) and treatment time (6 hours). The gene
expression profiles of SWT showed an excellent match to the
CMAP gene expression profile of estradiol-treated MCF-7 cells
(permutation p,0.00001). This finding is consistent with SWT’s
widely claimed use as an effective traditional Chinese medicine for
women’s diseases with a possible phytoestrogenic effect. The
profile of SWT also shows similarity to the CMAP profiles of
withaferin A, 15-delta prostaglandin J2 and resveratrol, which
have been reported to possess chemopreventive effects [43,44].
Results of KEGG pathway analysis found SWT and estradiol
shared certain commonly regulated pathways of ‘‘cell cycle
regulation’’, ‘‘p53 signaling’’ and ‘‘molecular mechanisms of
cancer’’, further supporting SWT’s phytoestrogenic effects.
However, the gene expression profiles for SWT and estradiol also
showed a significant difference. One of the most notable
differences is that the ability to alter gene expression in the Nrf2
pathway only exists for SWT, but not for estradiol. The role of
estrogens in the initiation and progression of breast cancer has
been well known [45]. However, there is a large body of evidence
that the consumption of phytoestrogens derived from plants and
TCM can decrease the risk of cancer although they display
estrogen-like activity [46]. These results support a notion that
SWT may not have the cancer-causing effects of estradiol, but only
have the beneficial cell protective activity.
Based on our previous work [25], the content of FA of the SWT
extract was found to be 0.076%, corresponding to 0.0194, 0.194,
and 1.94 mg/ml of FA, which were the concentrations tested in the
present study. Such dosage selection allows a comparison of the
activity of single compound (FA) with that of the TCM
formulation (SWT). However, our data showed that FA in all
the concentration tested only had subtle effects on global
transcription in MCF-7 cells, although FA has been suggested as
the chemical fingerprint for quality control of SWT products
[29,30,31]. In view of lack of activity on gene expression, FA
should not be used as a biological marker for activity of SWT.
The lack of expected gene expression change by FA may
partially be explained by the statistical limitations of the approach:
the sample size (n=3 for each treatment group) and the fact that
multiple tests of significance being done simultaneously may
contribute to false positive/negative findings. Although the
‘‘multiple testing’’ corrections by False Discovery Rate (FDR)
analysis were described in the text and Methods, such criteria may
be too stringent to identify differentially expressed genes from
treatment groups of FA and low concentration of SWT (Table 1).
The biological limitations for this study, as is the case for almost all
transcript profiling studies, is that there remains uncertainty about
the relationship between mRNA and protein expression, and the
relationship of both to function. Nevertheless, as indicated in
Figure 5, a functional assay of Nrf2 pathway strongly supports the
results obtained from microarray analysis.
In conclusion, gene expression profiles obtained by using
microarrays combined with bioinformatic mining of the CMAP
reference database can potentially shed light on the new molecular
mechanism of SWT. If SWT can be shown to have cancer
preventive potential, it has a great economic advantage because of
its low cost and low toxicity, which will have a profound impact on
human health. Further work is needed to determine the in vivo
relevance of the in vitro findings obtained from the present study.
This new approach proved to be powerful in an understanding of
mechanisms of actions for TCM as exemplified by our study with
SWT. In addition, the gene expression changes identified in this
study could be used as biomarkers which can be used for assessing
the intact quality of SWT. The genomic approach can be
integrated with traditional chromatography-based fingerprinting




Ferulic acid, 17 b-estradiol and DMSO were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
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The SWT products were obtained from the School of
Pharmacy, Chinese University of Hong Kong. These products
were manufactured under GMP condition at the Hong Kong
Institute of Biotechnology (Hong Kong, China) according to the
protocol described in Chinese Pharmacopoeia 2005 [47] with
modifications. Crude water extracts were prepared from powdered
SWT. Fresh extracts were prepared right before the experiment.
Three concentrations of SWT extract were prepared, 2.56 mg/
ml, 0.256 mg/ml and 0.0256 mg/ml for high (SH), medium (SM),
and low (SL) concentrations, respectively. The SH was prepared
by dissolving 2.56 mg SWT powder into 1 ml of PBS buffer,
followed by sonication for 30 min. The SM and SL were prepared
by dilute the SH 10 and 100 times using PBS, respectively. As
determined previously [25], the SL, SM and SH solutions contain
0.0194, 0.194, and 1.94 mg/ml of ferulic acid, respectively.
Cell lines and cell culture
The MCF-7 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA), cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1% non-essential amino acids, 100 unit/mL
penicillin, 100 mg/mL streptomycin, 1 mM sodium pyruvate, and
2 mM L-glutamine in an atmosphere of 5% CO2 at 37uC. The
cells were seeded in 6-well plates at a density of 1610
5 cells/ml.
After incubating for 24 hours and at least 4 days before treatment,
the medium was then replaced by hormone free medium which
contains phenol-red free DMEM medium supplemented with 5%
charcoal-dextrin stripped FBS (CD-FBS) to prevent the influence
of hormones or estrogen-like compounds in the regular culture
medium. The medium was changed every other day. The MCF-7
cells were then incubated with hormone free medium and treated
by 0.001% DMSO (vehicle control group, C), 0.1 mM1 7b-
estradiol (EM), 0.1, 1 or 10 mM of ferulic acid (equivalent to
0.0194, 0.194, and 1.94 mg/ml) ( FL, FM and FH), 0.0256, 0.256,
and 2.56 mg/ml SWT (SL, SM and SH) for 6 hours. Three
replicates for each of the eight treatment groups were included,
resulting in a total of 24 samples (wells). The detailed experimental
information including names and concentrations of the treatments
are shown in Figure 1 and Table 1.
RNA extraction
Total RNA were extracted using RNeasy Mini Kit (QIAGEN,
Valencia, California), following the manufacturer’s protocol. The
concentrations of RNA were measured by a NanoVue Plus (GE
Healthcare, Piscataway, NJ, USA) and adjusted to 0.2 mg/ml. The
RNA samples were stored at 280uC before further processing for
microarray analysis.
Microarray processing
RNA quality was checked using the RNA 6000 LabChip and
Agilent 2100 BioAnalyzer. Only high quality RNA with RNA
Integrity Number (RIN) .9.0 were used for microarray
experiments. The 24 RNA sample IDs were randomly ordered
and were blinded to the microarray core facility, the Clinical
Transcriptional Genomics Core at Cedars-Sinai Medical Center,
in order to minimize the impact of potential confounding factors
such as sample processing time and order. The gene expression
data were generated using 24 Affymetrix Human Genome U133
Plus 2.0 arrays (Santa Clara, CA, USA). Each U133 Plus 2.0 array
consists of 54,675 probe sets detecting over 47,000 transcripts.
The cRNA synthesis and labeling was carried out following
Affymetrix one-cycle sample preparation protocol. Briefly, bioti-
nylated cRNAs were prepared according to the standard
Affymetrix GeneChip protocol. One mg of total RNA from each
sample, along with poly A spikes (labeling control), were converted
to double-stranded cDNA with GeneChip One-Cycle cDNA
synthesis kit (Affymetrix). After second-strand synthesis, the cDNA
was purified with the GeneChip sample cleanup module
(Affymetrix). Biotinylated cRNAs were synthesized by in vitro
transcription using the Affymetrix GeneChip 39-Amplification kit.
The A260/280 ratio and yield of each of the cRNAs were
obtained. For each sample, 10 mg of biotinylated cRNA along
spiked controls (bioB, bioC, bioD and cre) was hybridized to a
Human Genome U133 Plus 2.0 array for 16 hours at 45uC.
Following hybridization, arrays were washed, stained and then
scanned with an Affymetrix GeneChipH 3000 7G scanner.
Real-time RT-PCR
To validate the microarray results, the MCF-7 cells were treated
in a separate experiment using the identical experiment conditions
and method as described above. One microgram of total RNA was
incubated with DNase I, and reverse-transcribed with oligo dT
using Superscript II RT-PCR (Invitrogen). One microliter of RT
product was amplified by primer pairs specific for HMOX1, NQO1,
SLC7A11, GCLM and GCLC. The GAPDH gene was used as a
normalizing control. The primer sequences are available upon
request. Relative gene expression was measured using the
GeneAmp 7300 Sequence Detection system (Applied Biosystems,
Foster City, CA, USA) using a SYBR Green protocol. For all
amplifications, a standard amplification program was used (1 cycle
of 50uC for 2 min, 1 cycle of 95uC for 10 min, 50 cycles of 95uC
for 15 s and 60uC for 1 min). At the end of PCR cycling steps,
data for each sample was displayed as a melting curve. The ABI
SDS software was used to determine a ‘‘Threshold Cycle’ (Ct),
which was the cycle number where the linear phase for each
sample reached the threshold detection level.
Luciferase reporter gene assay
The luciferase reporter construct pGL4.22-ARE was a gift from
Dr. Donna Zhang at the University of Arizona. It was generated
by cloning a 39-bp antioxidant responsive element (ARE)-
containing sequence from the promoter region of the NAD(P)H
quinone oxidoreductase 1 (NQO1) into the pGL4.22 vector
(Promega, Madison, WI, USA) [48]. The HEK293 or MCF-7 cells
were transfected with the pGL4.22-ARE plasmid and a constitu-
tively active renilla luciferase (pRL-TK-luc, from Promega; to
correct for tranfection efficiency) (40:1 ratio) using FuGENE HD
Transfection Reagent (Roche Applied Science, Indianapolis, IN,
USA) according to the manufacturer’s instructions. Twenty-four
hours after transfection, the cells were exposed to the extracts of
SWT or four herbal components for another 24 hours. Cell lysates
were used for determining luciferase activities of both firefly and
renilla by the dual luciferase reporter gene assay (Promega). Firefly
luciferase activity was normalized to renilla luciferase activity. The
experiment was carried out in triplicate and expressed as the mean
6 SD.
Microarray data analysis
Microarray data specifically generated for this study are
MIAME compliant. The raw data are available through the
National Center for Biotechnology Information’s Gene Expression
Omnibus (GEO series accession number: GSE23610). The
microarray gene expression data were imported to ArrayTrack
[49], a software system developed by the U.S. Food and Drug
Administration’s National Center for Toxicological Research for
the management, analysis, visualization and interpretation of
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set-level expression data were summarized from probe-level data
with Robust Multichip Average (RMA) [50] by taking all 24
microarrays together. Statistical testing and clustering analysis
were conducted using ArrayTrack. Additional calculations were
performed within JMP 7 (SAS Institute, Cary, NC, USA) and
MATLAB 7.10 (MathWorks, Natick, MA, USA). For each probe
set, log2-transformed intensity data were used in a two-sample t-
test to obtain a p value and a fold change (FC).
Quality assessment of the microarray data
Hierarchical clustering analysis combined with heatmap was
applied to evaluate the overall reproducibility and variation of 3
replicates within each group and the differences among the 8
groups. The log2-transformed expression intensities of 54,675
probe sets with RMA summarized data from 24 microarrays were
used to calculate the correlation coefficients between two gene
expression profiles and construct the heatmap. The quality of
microarray data generated in this study is excellent for identifying
differentially expressed genes.
Identification of differentially expressed genes
One important task in microarray data analysis is to identify a
list of differentially expressed genes between two conditions (e.g.
treatment versus control) [13,14]. Many methods have been used
for selecting differentially expressed genes and the choice of the
‘‘best’’ gene selection methods has been under extensive debate
[15,16]. In this study, genes differentially expressed between two
sample groups were selected following the recommendations of the
MAQC project [12,51]. Briefly, a t-test p value and a fold change
comparing a treatment group and the control were calculated for
each probe set. Probe sets with a p value greater than a pre-defined
cutoff (e.g. p.0.05) were removed and the remaining probe sets
were ranked according to the magnitude of fold changes. Genes
measured by the probe sets with a fold change (FC) greater than a
pre-defined threshold (e.g. FC.1.5) were considered as differen-
tially expressed. This straightforward approach of combining a
non-stringent p value filtering with a fold-change based ranking
has been found to generate more reproducible and reliable
differentially expressed genes [12,15,16,51,52]. The expression
profiles of the differentially expressed genes have been used as an
input to search reference gene expression data (i.e., CMAP
database) for treatments with similar expression profiles or to
identify pathways enriched with the differentially expressed genes.
To reduce the number of false-positive differentially expressed
genes among 54,675 probe sets, we controlled for the false-
discovery rate (FDR) at the level of 0.05 as described previously
[53]. However, the FDR criteria of 0.05 may be too stringent as
more than half of the genes identified using the above criteria
would be removed. Thus, although the criteria of p,0.05 and
FC.1.5 were used with low stringency, this is expected to detect
more genes truly associated with SWT at the expense of increasing
the number of false-positives to be validated by other bioinfor-
matic and experimental means.
Identification of pathways enriched with differentially
expressed genes
The lists of differentially expressed genes were then imported to
the Ingenuity Pathway Analysis (IPA) software (IngenuityH
Systems, www.ingenuity.com) to identify pathways that are
enriched with the genes. The probe sets were mapped to the
HUGO gene symbols within IPA software. When multiple probe
sets map to the same HUGO gene symbol, only the probe set with
the maximal absolute log2 fold change value was kept for
identifying enriched IPA canonical pathways. Probe sets that do
not map to any HUGO genes were discarded. For each canonical
pathway, the Fisher’s exact test p value was calculated to measure
the statistical significance of enrichment of the pathway of the
differentially expressed genes in relation with what would be
expected by chance from the total number of unique genes in the
input list. In addition, the ratio of the number of input genes that
are in the pathway to the total number of genes in the pathway
was calculated. The p value and the ratio indicate the levels of
impact the treatment has on the pathway. The pathways were
ranked according to p values, with the most significantly impacted
pathways are shown on the top.
The lists of differentially expressed genes were also imported to
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
[54,55,56]. The probe sets in each treatment group were mapped
to the HUGO gene symbols within the KEGG database, and the
pathways enriched with the differentially expressed genes
according to the Fisher’s exact test p values are considered to be
impacted by the treatments.
Comparison of gene expression profiles with the CMAP
reference database
To help better understand the underlying mechanisms of the
therapeutic effects of SWT, we used the gene expression profiles of
SWT treatments as queries to search the ‘‘Connectivity Map’’
(CMAP, http://www.broadinstitute.org/cMAP/) reference data-
base (Build 02), which contains more than 7,000 expression
profiles (instances) mainly from three cell lines (MCF-7, HL60 and
PC3) treated with 1,309 compounds [17]. The query to CMAP is
two lists of differentially expressed genes (listed as Affymetrix probe
sets), one for up-regulation and the other for down-regulation, in
which genes are ranked by the absolute log2 fold change values
with descending order. The similarity between the gene expression
profile of the query signature and that of a CMAP instance is
measured by the connectivity score, ranging from -1 to 1. A high
positive connectivity score indicates that the corresponding
perturbagen in the CMAP database may similarly induce the
expression change as the query agent. A high negative connectivity
score indicates that the corresponding perturbagen in the CMAP
database may reverse the expression effects of the query agent.
Multiple profiles may exist for the same CMAP chemical name
(due to different treatment concentrations, cell lines, or batches).
CMAP allows individually matched instances consolidated by
CMAP chemical name and cell line. Each combination of
chemical names and cell lines combination comes with a mean
connectivity score and a permutation p value, which indicates the
probability of enrichment of a set of instances in a list of all
instances by chance.
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